Heart Disease News and Research

Latest Heart Disease News and Research

SARRC awarded a $100,000 as the winner of the 2009 Arizona Benefits grant

The Southwest Autism Research & Resource Center (SARRC), a non-profit working to advance research and provide support for individuals with autism and their families, has been awarded a $100,000 grant as the winner of the 2009 Arizona Benefits grant, funded by health benefits company Humana Inc.

24 Oct 2009

Learn to recognise stroke symptoms and take action: World Stroke Organization

The theme of this year's World Stroke Day on 29th October is "What can I do?". As the World Stroke Organization says, everyone can do something: learn to recognise symptoms and take action, learn to recognise the risk factors and take action.

24 Oct 2009

University neurologists launch multiple sclerosis research study

Neurologists at the University at Buffalo are beginning a research study that could overturn the prevailing wisdom on the cause of multiple sclerosis (MS).

24 Oct 2009

Health Canada issues medical device license for IMRISNV and IMRIScardio systems

IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced that Health Canada has issued a medical device licence for the Company's IMRX system permitting IMRIS to market its newest products, IMRISNV and IMRIScardio in Canada.

24 Oct 2009

PPA reaches historic milestone; helps the six millionth person

After visiting more than 3,000 cities in all 50 states, the Partnership for Prescription Assistance (PPA) has reached a historic milestone today by helping the six millionth person at an event in Harrisburg, Pennsylvania.

24 Oct 2009

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan’s drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants’ proposed generic products until the last to expire of the infringed patents, which is 2022.

24 Oct 2009

Clinical results of FlexStent Femoropopliteal Self Expanding Stent System presented

Interim six month clinical results on the use of the FlexStent Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery were presented today at the VIVA conference by Dr. William Gray of NY Columbia-Presbyterian Hospital.

24 Oct 2009

Nutri5, an effective natural product for the relief of menopausal symptoms

Earlier this year, the BBC reported that "HRT - Hormone Replacement Therapy - can shrink women's brains"1, after a study was published which showed that brain volume in women taking HRT was smaller in two key areas involved in thinking and memory.

23 Oct 2009

Physicians' recognize benefits of genetic testing; say formal education required to put it into practice

Medco Health Solutions, Inc.(NYSE: MHS) and the American Medical Association (AMA) today announced the findings of a national benchmark survey on physicians' acceptance, use and education regarding pharmacogenomic testing.

23 Oct 2009

Modified NAGA: New enzyme for enzyme replacement therapy

A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure. The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease.

23 Oct 2009

Follow healthy lifestyle to overturn genetic predisposition to heart disease

When it comes to heart disease, lifestyle usually trumps genetics, says noted genetic researcher Dr. Robert Hegele, Heart and Stroke Foundation of Canada Lecturer at the Canadian Cardiovascular Congress 2009.

23 Oct 2009

Workers with MetS can cost employers up to $5,867 in health care annually: Study

Someone healthy enough to work could still cost an employer more than $4,000 annually in unnecessary health care costs.

23 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

ISHLT Infectious Disease Council issues new H1N1 advisory for cardiothoracic transplantation programs

Each year 3-5 million people have severe cases and 250-500,000 die from complications of seasonal influenza world-wide. This year, the novel 2009 H1N1 (nH1N1) influenza, previously called swine flu, has reached pandemic status.

23 Oct 2009

Practical guidance for cardiothoracic transplant programs in view of H1N1 flu pandemic

23 Oct 2009

Newcardio expert to present clinical validation data of Phase I and TQT studies on ECG

NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dr. Sam George, NewCardio's Senior Consultant, will join a distinguished roster of speakers, moderators and panelists at the Cardiac Safety Research Consortium (CSRC) annual meeting in Maryland at the Marriot Bethesda, Pooks Hill location on October 29-30, 2009.

23 Oct 2009

Quality of U.S. health care was virtually stagnant in 2008, says NCQA report

A report released today by the National Committee for Quality Assurance (NCQA) finds that the quality of U.S. health care was virtually stagnant in 2008, a disturbing slowdown after a decade of improvements. The across-the-board trend was seen in care provided to people with private insurance coverage as well as in Medicare and Medicaid.

23 Oct 2009

New technique developed to transform regular body cells into artificial stem cells

Scientists have overcome a key barrier to the clinical use of stem cells with a technique which transforms regular body cells into artificial stem cells without the need for introducing foreign genetic materials, which could be potentially harmful. The research, published in STEM CELLS, suggests that cells taken from a patient's eye can be "reprogrammed" to replace or restore cells lost to degenerative diseases.

23 Oct 2009

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.

23 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Heart Disease News and Research

Latest Heart Disease News and Research

SARRC awarded a $100,000 as the winner of the 2009 Arizona Benefits grant

Learn to recognise stroke symptoms and take action: World Stroke Organization

University neurologists launch multiple sclerosis research study

Health Canada issues medical device license for IMRISNV and IMRIScardio systems

PPA reaches historic milestone; helps the six millionth person

U.S. District Court rules in favor of Allergan in its patent infringement suit against Exela PharmSci

Clinical results of FlexStent Femoropopliteal Self Expanding Stent System presented

Nutri5, an effective natural product for the relief of menopausal symptoms

Physicians' recognize benefits of genetic testing; say formal education required to put it into practice

Modified NAGA: New enzyme for enzyme replacement therapy

Follow healthy lifestyle to overturn genetic predisposition to heart disease

Workers with MetS can cost employers up to $5,867 in health care annually: Study

Shire announces new pharmacokinetic data of ADHD medication

ISHLT Infectious Disease Council issues new H1N1 advisory for cardiothoracic transplantation programs

Practical guidance for cardiothoracic transplant programs in view of H1N1 flu pandemic

Newcardio expert to present clinical validation data of Phase I and TQT studies on ECG

Quality of U.S. health care was virtually stagnant in 2008, says NCQA report

New technique developed to transform regular body cells into artificial stem cells

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Heart Disease News and Research

Latest Heart Disease News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in